|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
G protein-coupled receptor 120 (GPR 120) levels are reduced in pediatric OSA and obesity (particularly when both are present) and may play a role in modulating the degree of insulin resistance.
|
24790272 |
2014 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of physical exercise and ω3 food sources could provide a new strategy against obesity through the modulation of hepatic GPR120 and an increase in exercise performance.
|
30771734 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gpr120-deficient mice develop obesity and both impaired fasting glucose and glucose intolerance under a high-fat diet.
|
26025001 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, GPR120, the sensing receptor for long-chain free fatty acids, represents a novel drug target for the treatment of obesity and diabetes.
|
23317787 |
2013 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
p.R270H (rs116454156) in the long chain fatty acid 7TM receptor FFAR4 (GPR120) which results in impaired Gαq (Gq) coupled signalling, has been associated with obesity.
|
27068006 |
2016 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stratifying the patients with the GPR120 270H variant on the basis of their PNPLA3 polymorphism, we demonstrated a significant interaction effect on ALT levels (P = 0.00001), suggesting a driving effect of the PNPLA3 148M allele on liver injury in children with obesity carrying this variant.
|
25250621 |
2014 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that GPR120 activation is protective against lipotoxicity-induced pancreatic β-cell dysfunction, via the mediation of PDX1 expression and inhibition of islet inflammation, and that GPR120 activation may serve as a preventative and therapeutic target for obesity and diabetes.
|
30523046 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the association between GPR120 and obesity, and the FA effects on its expression.
|
24913719 |
2014 |
|
RETINAL DYSTROPHY, IRIS COLOBOMA, AND COMEDOGENIC ACNE SYNDROME
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 10
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Diabetes
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Since PHS is rich in the plasma membrane of yeast, our results imply that PHS found in fermented food could have effects on anti-diabetes through activation of GPR120.
|
29373685 |
2018 |
|
Diabetes
|
0.060 |
Biomarker
|
disease |
BEFREE |
GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported.
|
28374589 |
2017 |
|
Diabetes
|
0.060 |
Biomarker
|
disease |
BEFREE |
Since FFA4 is currently an attractive drug target for treatment of metabolic disorders such as diabetes and obesity, understanding its role in cancer progression is critical towards the drug discovery process.
|
29452095 |
2018 |
|
Diabetes
|
0.060 |
Biomarker
|
disease |
BEFREE |
FFAR4 has been considered as a potential target for metabolic diseases, including diabetes.
|
31580060 |
2019 |
|
Diabetes
|
0.060 |
Biomarker
|
disease |
BEFREE |
Therefore, GPR120, the sensing receptor for long-chain free fatty acids, represents a novel drug target for the treatment of obesity and diabetes.
|
23317787 |
2013 |
|
Diabetes
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings indicate that GPR120 activation is protective against lipotoxicity-induced pancreatic β-cell dysfunction, via the mediation of PDX1 expression and inhibition of islet inflammation, and that GPR120 activation may serve as a preventative and therapeutic target for obesity and diabetes.
|
30523046 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the exploration cohort, FFAR4 was demonstrated as an independent prognostic factor for recurrences (HR: 2.183, 95% CI: 1.360-3.504, P = 0.001) and breast cancer-specific deaths (HR: 2.102, 95% CI: 1.173-3.766, P = 0.013) in HRPBC cases.
|
30795784 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of G protein-coupled receptor 120 (GPR120) was analyzed by immunohistochemistry in the biopsies of primary breast cancer who subsequently underwent preoperative neoadjuvant chemotherapy.
|
30738829 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings indicate that GPR120 acts as a cancer-promoting receptor in the development of breast cancer.
|
30520776 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Thus, these observations indicated that GPR120 promotes breast cancer cell growth, whereas ω-3 PUFA-induce breast cancer cell apoptosis independently of GPR120.
|
28980737 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Thus, these observations indicated that GPR120 promotes breast cancer cell growth, whereas ω-3 PUFA-induce breast cancer cell apoptosis independently of GPR120.
|
28980737 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the exploration cohort, FFAR4 was demonstrated as an independent prognostic factor for recurrences (HR: 2.183, 95% CI: 1.360-3.504, P = 0.001) and breast cancer-specific deaths (HR: 2.102, 95% CI: 1.173-3.766, P = 0.013) in HRPBC cases.
|
30795784 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings indicate that GPR120 acts as a cancer-promoting receptor in the development of breast cancer.
|
30520776 |
2019 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of G protein-coupled receptor 120 (GPR120) was analyzed by immunohistochemistry in the biopsies of primary breast cancer who subsequently underwent preoperative neoadjuvant chemotherapy.
|
30738829 |
2019 |
|
Metabolic Syndrome X
|
0.030 |
Biomarker
|
disease |
BEFREE |
The long chain free fatty acid receptor 4 (FFA4/GPR120) has recently been recognized as lipid sensor playing important roles in nutrient sensing and inflammation and thus holds potential as a therapeutic target for type 2 diabetes and metabolic syndrome.
|
28148462 |
2017 |